The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.

Using population based data, researchers found a 10 fold increase prevalence of SSc in first degree relatives. That equates to a relative risk of 81. Genetic factors appear to be important in the risk for scleroderma.

ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.

Low back pain (LBP) is the fifth most common reason for all physician visits in the United States and nearly 25% of all U.S. adults have had LBP in the  last 3 months and nearly 6% reported at least 1 episode of severe acute low back pain in the last 1-year.

Low back pain (LBP) is a highly prevalent public health problem. Not surprisingly, imaging of LBP is also an expensive and often overused diagnostic tool.  

The Washington Post recently interviewed Dr. Eliza Chakavarty of the OMRF about the evolution in attitudes and outcomes of lupus women who wish to get pregnant.

The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).

Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.

A Lancet meta-analysis has reviewed the preventative effects of low-molecular-weight heparin (LMWH) on placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate.

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

The risk of developing ankylosing spondylitis (AS) if you are HLA-B27+ and a first degree relative is often said to be 20%.

The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.

The diagnosis of periodic fevers is unified by undiagnosed but recurrent fever. Unfortunately the diagnosis of these disorders is hampered by their infrequency, protean features and a lack of clear criteria. Even more problematic is knowing who should be tested and for which monogenic marker?

Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.

The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.

Muscle involvement in immune-mediated necrotizing myopathy (IMNM) was more extensive compared with other inflammatory myopathies, according to a retrospective chart review.

Children with juvenile idiopathic arthritis (JIA) treated with biologic therapies were at no higher risk for hospitalized infections than those treated with methotrexate alone, But, higher rates were seen with anakinra in systemic JIA.

Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.

Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.